Evaluation of the Therapeutic Effects of QuickOpt Optimization in Chinese Patients with Chronic Heart Failure Treated by Cardiac Resynchronization
Ji Yan,Shu Zhang,Dejia Huang,Xiaolin Xue,Jing Xu,Qianmin Tao,Weize Zhang,Zheng Zhang,Wei Hua,Yanchun Liang,Baopeng Tang,Wei Xu,Geng Xu,Xuejun Ren,Jingfeng Wang,Tao Guo,Shaobin Jia,Yugang Dong,Hong Jiang,Guosheng Fu,Liguang Zhu,Lin Chen,Fuli Tian,Feng Ling,Jianmei Li,Xiaoyong Qi,Yinglu Hao,Yutang Wang,Liangrong Zheng,Xiaoqun Pu,Farong Shen,Guangping Li,Hui Li,Fang Peng
DOI: https://doi.org/10.1038/s41598-018-22525-0
IF: 4.6
2018-01-01
Scientific Reports
Abstract:In this trial, long-term therapeutic effects and clinical improvements in Chinese chronic heart failure patients optimized by QuickOpt or echocardiography were compared for atrioventricular (AV) and interventricular (VV) delay optimizations after cardiac resynchronization therapy (CRT) with pacing (CRT-P) or with pacing and defibrillator (CRT-D) therapy. One hundred and ninety-six subjects (50%) had dilated cardiomyopathy, 108 (27.6%) had ischemic heart disease and 112 (28.6%) were hypertensive and were randomized into QuickOpt (198) or echocardiographic optimization (control) (194) groups at ≤2-weeks post-implantation. Programmed AV/VV delay was optimized at baseline and at 3 and 6 months. Left ventricular end-systolic volume (LVESV), New York Heart Association (NYHA) class, specific activity scale (SAS), and the six-minute walk tests (6MWT) were evaluated by blinded researchers at 12 months. Of the QuickOpt group, LVESV decreased significantly by 24.7% ± 33.9% compared with baseline, while LVESV of Controls decreased by 25.1% ± 36.1% (P = 0.924). NYHA class, SAS and 6MWT also improved similarly in both groups at 12 months. Mortality in both groups was not significantly different (11.0% vs 7.6%, P = 0.289). However, there was a significant difference in the time required for optimization by QuickOpt compared with echocardiography (3.33 ± 3.11 vs 58.79 ± 27.03 minutes, P < 0.000).